Cargando…

Impact of pseudoprogression and treatment beyond progression on outcome in patients with non-small cell lung cancer treated with immune checkpoint inhibitors

BACKGROUND: Immune checkpoint inhibitors (ICI) have become an important treatment option for non-small cell lung cancer (NSCLC). We aimed to evaluate the clinical impact of pseudoprogression (PsP) and treatment beyond RECIST1.1-defined progressive disease (TBP) on outcome in NSCLC patients treated w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Won, Sang Eun, Park, Hyo Jung, Byun, Sangil, Pyo, Junhee, Kim, Jwa Hoon, Choi, Chang-Min, Lee, Jae Cheol, Lee, Dae Ho, Kim, Sang-We, Yoon, Shinkyo, Kim, Kyung Won
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458612/ https://www.ncbi.nlm.nih.gov/pubmed/32923136 http://dx.doi.org/10.1080/2162402X.2020.1776058

Ejemplares similares

Real‐world utility of next‐generation sequencing for targeted gene analysis and its application to treatment in lung adenocarcinoma
por: Kim, Jwa Hoon, et al.
Publicado: (2021)

Impact of gender on response to immune checkpoint inhibitors in patients with non-small cell lung cancer undergoing second- or later-line treatment
por: Choi, Myeong Geun, et al.
Publicado: (2022)

Comparison of T790M Acquisition Between Patients Treated with Afatinib and Gefitinib as First-Line Therapy: Retrospective Propensity Score Matching Analysis
por: Yoon, Byung Woo, et al.
Publicado: (2019)

Definition, Incidence, and Challenges for Assessment of Hyperprogressive Disease During Cancer Treatment With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis
por: Park, Hyo Jung, et al.
Publicado: (2021)

Incidence of Immune-Mediated Pseudoprogression of Lymphoma Treated with Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis
por: Lee, Amy Junghyun, et al.
Publicado: (2021)

Prognostic value of MRI volumetric parameters in non-small cell lung cancer patients after immune checkpoint inhibitor therapy: comparison with response assessment criteria
por: Roh, Yun Hwa, et al.
Publicado: (2023)

Recurrence-associated gene signature in patients with stage I non-small-cell lung cancer
por: Cho, Su Han, et al.
Publicado: (2021)

Outcomes according to initial and subsequent therapies following intracranial progression in patients with EGFR-mutant lung cancer and brain metastasis
por: Hyun, Dong-gon, et al.
Publicado: (2020)

Different prognostic implications of hepatic metastasis according to front-line treatment in non-small cell lung cancer: a real-world retrospective study
por: Choi, Myeong Geun, et al.
Publicado: (2021)

Optimal Definition of Oligometastasis Showing Survival Benefits of Local Therapies during Tyrosine Kinase Inhibitor Treatment
por: Jang, Yoon Jung, et al.
Publicado: (2023)

Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung
por: Jang, Yoon Jung, et al.
Publicado: (2021)

Evolution of Radiological Treatment Response Assessments for Cancer Immunotherapy: From iRECIST to Radiomics and Artificial Intelligence
por: Kim, Nari, et al.
Publicado: (2022)

Comparison of RECIST 1.1 and iRECIST in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Park, Hyo Jung, et al.
Publicado: (2021)

Immune Checkpoint Inhibitor-Induced Cerebral Pseudoprogression: Patterns and Categorization
por: Urban, Hans, et al.
Publicado: (2022)

Pseudoprogression and Immunotherapy Phenomena
por: Waxman, Elizabeth S., et al.
Publicado: (2020)

The impact of systematic assessment for adverse events on unscheduled hospital utilization in patients receiving neoadjuvant or adjuvant chemotherapy: A retrospective multicenter study
por: Kim, Jwa Hoon, et al.
Publicado: (2021)

Integrin αvβ3 Induces HSP90 Inhibitor Resistance via FAK Activation in KRAS-Mutant Non–Small Cell Lung Cancer
por: Yoon, Shinkyo, et al.
Publicado: (2022)

The Prognosis and the Role of Adjuvant Chemotherapy for Node-Positive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by Surgery
por: Jeong, Hyehyun, et al.
Publicado: (2022)

Unusual radiologic manifestation of pseudoprogression in pulmonary metastases after durvalumab treatment in metastatic bladder urothelial cancer
por: Kim, Eun Young, et al.
Publicado: (2019)

Mutational Profiling of Malignant Mesothelioma Revealed Potential Therapeutic Targets in EGFR and NRAS
por: Kim, Jeong Eun, et al.
Publicado: (2018)

Risk of tuberculosis in patients with cancer treated with immune checkpoint inhibitors: a nationwide observational study
por: Bae, Seongman, et al.
Publicado: (2021)

Treatment Efficacy of Immune Checkpoint Inhibitors for Patients with Advanced or Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
por: Pyo, Junhee, et al.
Publicado: (2021)

Feasibility, safety, and adequacy of research biopsies for cancer clinical trials at an academic medical center
por: Lee, Kyoungmin, et al.
Publicado: (2019)

HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells
por: Park, Kang-Seo, et al.
Publicado: (2018)

Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer
por: Soria, Francesco, et al.
Publicado: (2018)

Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors
por: Mönch, Sebastian, et al.
Publicado: (2023)

Increased incidence of chemoport-related thrombosis in patients with colorectal cancer receiving bevacizumab: A single-institutional experience
por: Kim, Jwa Hoon, et al.
Publicado: (2018)

Primary hepatic mixed germ cell tumor in an adult
por: Sung, Hyun-Jung, et al.
Publicado: (2021)

Nanoindentation for Monitoring the Time-Variant Mechanical Strength of Drug-Loaded Collagen Hydrogel Regulated by Hydroxyapatite Nanoparticles
por: Jung, Hyo Gi, et al.
Publicado: (2021)

A unique expression pattern of LAG3 distinct from that of other immune checkpoints in diffuse large B‐cell lymphoma
por: Lee, Hyunjee, et al.
Publicado: (2023)

Multiple oligodendroglioma with pseudoprogression
por: Matsuyama, Junko
Publicado: (2012)

Pseudoprogression of brain tumors
por: Thust, Stefanie C., et al.
Publicado: (2018)

Comparison of screening strategies for prevalent vertebral fractures in South Korea: vertebral fracture assessment vs. spine radiography
por: Oh, Sung-Hee, et al.
Publicado: (2018)

Pseudoprogression and peritumoral edema due to intratumoral necrosis after Gamma knife radiosurgery for meningioma
por: Jung, In-Ho, et al.
Publicado: (2022)

Pseudoprogression Disease in a Patient with Small Cell Lung Cancer on Immune Checkpoint Inhibitor Therapy
por: Zhu, Wanshan, et al.
Publicado: (2023)

True Progression versus Pseudoprogression in the Treatment of Glioblastomas: A Comparison Study of Normalized Cerebral Blood Volume and Apparent Diffusion Coefficient by Histogram Analysis
por: Song, Yong Sub, et al.
Publicado: (2013)

Immune checkpoint inhibitors in patients with pretreated HodgkinÊs lymphoma: a Korean single-center, retrospective study
por: Hur, Joon Young, et al.
Publicado: (2020)

Soluble immune checkpoint molecules in patients with antineutrophil cytoplasmic antibody-associated vasculitis
por: Pyo, Jung Yoon, et al.
Publicado: (2022)

Pseudoprogression in low-grade glioma
por: Slater, Jason M., et al.
Publicado: (2019)

Impact of clinicopathologic features on leptomeningeal metastasis from lung adenocarcinoma and treatment efficacy with epidermal growth factor receptor tyrosine kinase inhibitor
por: Kwon, Byoung Soo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qmmefcfvabt0m5cpscenl9jc1q